Bristol Myers: new data in psoriasis
(CercleFinance.com) - Bristol Myers Squibb today announced new long-term data for Sotyktu TM (deucravacitinib) showing sustained clinical efficacy for up to two years with continuous treatment in moderate-to-severe plaque psoriasis.
These results add to the body of available data and reinforce the efficacy profile of Sotyktu, a once-daily oral selective and allosteric tyrosine kinase 2 (TYK2) inhibitor, in the treatment of moderate-to-severe plaque psoriasis.
The new analysis will be presented at the European Academy of Dermatology and Venereology Congress 2022 as part of 26 company-sponsored scientific presentations.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
These results add to the body of available data and reinforce the efficacy profile of Sotyktu, a once-daily oral selective and allosteric tyrosine kinase 2 (TYK2) inhibitor, in the treatment of moderate-to-severe plaque psoriasis.
The new analysis will be presented at the European Academy of Dermatology and Venereology Congress 2022 as part of 26 company-sponsored scientific presentations.
Copyright (c) 2022 CercleFinance.com. All rights reserved.